FibroGen (NASDAQ:FGEN) Receiving Somewhat Favorable Media Coverage, Accern Reports
Media stories about FibroGen (NASDAQ:FGEN) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. FibroGen earned a news sentiment score of 0.24 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 0 out of 100, meaning that recent press coverage is extremely unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news articles that may have effected Accern’s rankings:
- FibroGen, Inc (NASDAQ:FGEN) Stock Closed 16.6% Above Its 50 Day Average (highlightpress.com)
- Fibrogen Inc Up 37.0% Since SmarTrend Uptrend Call (FGEN) (mysmartrend.com)
- FibroGen, Inc (NASDAQ:FGEN) Stock Closed Much Higher Than Its 50 Day Average – Highlight Press (highlightpress.com)
- Needle Action Activity Spotted in FibroGen Inc (FGEN) – Evergreen Caller (evergreencaller.com)
- Long Term: FibroGen, Inc. (FGEN) strong Trend – Stocks Gallery (stocksgallery.com)
Several equities analysts have recently weighed in on FGEN shares. Jefferies Group LLC initiated coverage on FibroGen in a research report on Monday, July 10th. They issued a “buy” rating and a $50.00 price target for the company. BidaskClub raised FibroGen from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 24th. Stifel Nicolaus reaffirmed a “buy” rating and set a $38.00 price target (up previously from $32.00) on shares of FibroGen in a research note on Thursday, June 22nd. William Blair reissued an “outperform” rating on shares of FibroGen in a research note on Monday, June 26th. Finally, Citigroup Inc. reissued a “buy” rating and issued a $48.00 target price on shares of FibroGen in a research note on Monday, June 26th. One analyst has rated the stock with a sell rating, seven have given a buy rating and one has given a strong buy rating to the company. FibroGen presently has a consensus rating of “Buy” and a consensus price target of $42.17.
FibroGen (NASDAQ FGEN) traded down 0.15% during mid-day trading on Friday, hitting $33.50. The company had a trading volume of 200,985 shares. FibroGen has a 1-year low of $15.60 and a 1-year high of $34.25. The firm’s market capitalization is $2.34 billion. The company has a 50 day moving average of $28.77 and a 200 day moving average of $25.52.
FibroGen (NASDAQ:FGEN) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($0.52) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.63) by $0.11. The firm had revenue of $26.89 million for the quarter, compared to the consensus estimate of $26.02 million. FibroGen had a negative net margin of 37.60% and a negative return on equity of 36.41%. Analysts predict that FibroGen will post ($1.85) earnings per share for the current fiscal year.
In other FibroGen news, VP Pat Cotroneo sold 4,000 shares of the firm’s stock in a transaction on Thursday, July 6th. The shares were sold at an average price of $34.00, for a total transaction of $136,000.00. Following the transaction, the vice president now directly owns 167,366 shares of the company’s stock, valued at approximately $5,690,444. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider K Peony Yu sold 5,000 shares of the firm’s stock in a transaction on Monday, July 10th. The stock was sold at an average price of $32.98, for a total transaction of $164,900.00. Following the completion of the sale, the insider now owns 216,507 shares of the company’s stock, valued at approximately $7,140,400.86. The disclosure for this sale can be found here. Insiders sold a total of 383,128 shares of company stock worth $11,174,949 over the last ninety days. Insiders own 14.90% of the company’s stock.
WARNING: “FibroGen (NASDAQ:FGEN) Receiving Somewhat Favorable Media Coverage, Accern Reports” was first published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/07/16/fibrogen-fgen-earns-news-sentiment-score-of-0-24-updated-updated-updated.html.
FibroGen, Inc is a science-based biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapeutics to treat serious unmet medical needs. Its lead product candidate is roxadustat (FG-4592). It is also engaged in developing products, such as FG-6874, FG-3019 and FG-5200.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.